中药通过调节肠道菌群干预冠心病研究进展  

Research Progress on the Intervention of Traditional Chinese Medicine in Coronary Heart Disease by Regulating Intestinal Microbiota

作　　者：裴腾勃 马艳侠[2] 黄刚 解晖 苏彦娥 吉锋 PEI Tengbo;MA Yanxia;HUANG Gang;XIE Hui;SU Yan e;JI Feng(Affiliated Hospital of Shaanxi University of Chinese Medicine,Xianyang 712000,China;Shaanxi University of Chinese Medicine,Xianyang 712046,China)

机构地区：[1]陕西中医药大学附属医院,陕西咸阳712000 [2]陕西中医药大学,陕西咸阳712046

出　　处：《陕西中医药大学学报》2025年第2期128-133,共6页Journal of Shaanxi University of Chinese Medicine

基　　金：陕西省教育厅重点实验室项目(23JS012)。

摘　　要：随着临床对肠道菌群研究的不断深入,越来越多的研究发现肠道菌群在维护人类健康和调控疾病方面发挥着重要的作用,其中肠道菌群和冠心病之间的相互关系逐渐被人们所认知,为治疗冠心病提供了新的方向。传统中药具有多成分、多靶点的治疗优势,对冠心病防治具有显著作用,但具体作用机制尚不明确。故从肠道菌群角度,综述了单味中药及中药方剂通过调节肠道菌群干预冠心病及其危险因素的研究,旨在为进一步探究中药调节肠道菌群干预冠心病的相关机制提供一定参考依据。With the continuous deepening of clinical research on gut microbiota,more and more studies have found that gut microbiota plays an important role in maintaining human health and regulating diseases.The interrelationship between gut microbiota and coronary heart disease is gradually being recognized,providing new directions for the treatment of coronary heart disease.Traditional Chinese medicine has the therapeutic advantage of multiple components and targets,and has a significant effect on the prevention and treatment of coronary heart disease.However,the specific mechanism of action is not yet clear.This article reviews the research on the intervention of single traditional Chinese medicine and traditional Chinese medicine formulas in coronary heart disease and its risk factors by regulating gut microbiota from the perspective of gut microbiota.The aim is to provide a certain reference basis for further exploring the relevant mechanisms of traditional Chinese medicine regulating gut microbiota intervention in coronary heart disease.

关 键 词：中医药 肠道菌群 冠心病 代谢产物 

分 类 号：R259[医药卫生—中西医结合]